WO2010083253A3 - Cd47 related compositions and methods for treating immunological diseases and disorders - Google Patents
Cd47 related compositions and methods for treating immunological diseases and disorders Download PDFInfo
- Publication number
- WO2010083253A3 WO2010083253A3 PCT/US2010/020945 US2010020945W WO2010083253A3 WO 2010083253 A3 WO2010083253 A3 WO 2010083253A3 US 2010020945 W US2010020945 W US 2010020945W WO 2010083253 A3 WO2010083253 A3 WO 2010083253A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorders
- methods
- immunological diseases
- related compositions
- fusion polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14469509P | 2009-01-14 | 2009-01-14 | |
US61/144,695 | 2009-01-14 | ||
US17493909P | 2009-05-01 | 2009-05-01 | |
US61/174,939 | 2009-05-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010083253A2 WO2010083253A2 (en) | 2010-07-22 |
WO2010083253A3 true WO2010083253A3 (en) | 2010-12-29 |
Family
ID=42340280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/020945 WO2010083253A2 (en) | 2009-01-14 | 2010-01-13 | Cd47 related compositions and methods for treating immunological diseases and disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010083253A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108864290B (en) * | 2017-05-08 | 2021-12-07 | 上海津曼特生物科技有限公司 | Bispecific recombinant protein and application thereof |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9566347B2 (en) | 2011-02-07 | 2017-02-14 | The Trustees Of The University Of Pennsylvania | Peptides and methods using same |
CA2838478A1 (en) * | 2011-06-16 | 2012-12-20 | Novartis Ag | Soluble proteins for use as therapeutics |
CN110066341B (en) | 2012-12-17 | 2023-01-31 | Pf阿根图姆知识产权控股有限责任公司 | Proteins, conjugates, pharmaceutical compositions, DNA constructs, host cells, and methods of making human SIRP alpha fusion proteins |
US10329354B2 (en) | 2013-09-18 | 2019-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
ES2857109T3 (en) * | 2015-05-18 | 2021-09-28 | Ab Initio Biotherapeutics Inc | SIRP Polypeptide Compositions and Methods of Use |
CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
EP3534964A4 (en) | 2016-11-03 | 2020-07-15 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
JP7262440B2 (en) | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス,インコーポレーテッド | Anti-CD47 antibody and uses thereof |
TW201910349A (en) * | 2017-08-10 | 2019-03-16 | 美商格里佛診斷方法股份有限公司 | Compositions, methods and/or kits comprising a recombinant human CD38 extracellular region |
EP3706775A4 (en) | 2017-11-06 | 2021-09-01 | Trillium Therapeutics Inc. | Cd47 blockade with radiation therapy |
JP7557920B2 (en) | 2018-09-04 | 2024-09-30 | ファイザー・インク | CD47 blockade in combination with PARP inhibition for the treatment of disease - Patents.com |
MX2021015452A (en) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Flt3l-fc fusion proteins and methods of use. |
US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
CN114599392A (en) | 2019-10-31 | 2022-06-07 | 四十七公司 | anti-CD 47 and anti-CD 20 based treatment of leukemia |
US11845723B2 (en) | 2019-12-24 | 2023-12-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
TW202302145A (en) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer |
WO2022229818A1 (en) | 2021-04-27 | 2022-11-03 | Pf Argentum Ip Holdings Llc | Enhancement of cd47 blockade therapy with dhfr inhibitors |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
JP2024522594A (en) | 2021-06-23 | 2024-06-21 | ギリアード サイエンシーズ, インコーポレイテッド | Diacylglycerol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023073580A1 (en) | 2021-10-29 | 2023-05-04 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
WO2023079438A1 (en) | 2021-11-08 | 2023-05-11 | Pfizer Inc. | Enhancement of cd47 blockade therapy with anti-vegf agents |
WO2023110824A1 (en) * | 2021-12-15 | 2023-06-22 | Novo Nordisk A/S | Novel integrin associated protein (iap) |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
CA3239528A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
EP4245756B1 (en) | 2022-03-17 | 2024-10-09 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (en) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | Combination therapy for treating colorectal cancer |
US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
WO2024159160A1 (en) * | 2023-01-27 | 2024-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Combination adoptive immune cell and anti-cd47 therapy and related compositions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044857A1 (en) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
US20080131431A1 (en) * | 2006-05-15 | 2008-06-05 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
-
2010
- 2010-01-13 WO PCT/US2010/020945 patent/WO2010083253A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044857A1 (en) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
US20080131431A1 (en) * | 2006-05-15 | 2008-06-05 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
Non-Patent Citations (2)
Title |
---|
HEBA 0. BARAZI ET AL.: "Regulation of Integrin Function by CD47 Ligands", JB C, vol. 277, no. 45, 8 November 2002 (2002-11-08), pages 42859 - 42866 * |
XIJUN YU ET AL.: "Engagement of CD47 Inhibits the Contact Hypersensitivity Response Via the Suppression of Motility and B7 Expression by Langerhans Cells", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 126, 2 February 2006 (2006-02-02), pages 797 - 807 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108864290B (en) * | 2017-05-08 | 2021-12-07 | 上海津曼特生物科技有限公司 | Bispecific recombinant protein and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2010083253A2 (en) | 2010-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010083253A3 (en) | Cd47 related compositions and methods for treating immunological diseases and disorders | |
WO2007133811A3 (en) | Cd47 related compositions and methods for treating immunological diseases and disorders | |
PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
WO2012016073A3 (en) | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions | |
MX358137B (en) | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use. | |
MX348071B (en) | Fc variants. | |
MX340971B (en) | Monomeric antibody fc. | |
NZ728042A (en) | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use | |
MX347077B (en) | Active protease-resistant antibody fc mutants. | |
HK1209034A1 (en) | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function fc fc | |
WO2011028344A3 (en) | Interleukin-1 receptor antagonist compositions and methods of making and using same | |
EA201290567A1 (en) | PREPARATION OF HETEROLOGICAL POLYPEPTIDES IN MICROWATEREDES, EXTRA-CELLED MICROWAVE-ALONG CALVES, COMPOSITIONS AND METHODS OF THEIR RECEIVING AND APPLICATION | |
WO2014144960A3 (en) | Fc variants | |
WO2010099219A3 (en) | Designer ligands of tgf-beta superfamily | |
MX350273B (en) | Fusion proteins for treating metabolic disorders. | |
WO2012142515A3 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
WO2015007536A3 (en) | Fusokines involving cytokines with strongly reduced receptor binding affinities | |
MX2012007318A (en) | Tetravalent cd47-antibody constant region fusion protein for use in therapy. | |
PL2919801T3 (en) | Stable pharmaceutical composition of the tnfr:fc fusion protein etanercept | |
IN2015DN01115A (en) | ||
MY160995A (en) | Polypeptides with permease activity | |
WO2009105669A3 (en) | Angiogenesis inhibition | |
WO2011153276A3 (en) | Stable, functional chimeric cellobiohydrolase class i enzymes | |
MX2012013735A (en) | Neuregulin isoforms, neuregulin polypeptides and uses thereof. | |
WO2013183032A3 (en) | Humanized anti-trka antibodies with amino acid substitutions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10732058 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10732058 Country of ref document: EP Kind code of ref document: A2 |